Another randomized experiment assessing silymarin's impact on biomarkers of the hepatic inflammatory process, such as ALT and AST, in individuals with acute clinical hepatitis of any origin revealed no discernible change. This evidence concerns the gene GPT and hepatitis A virus infection.